mouse monoclonal anti-brafv600e antibody, clone ve1 (Spring Bioscience)
90
Structured Review
Spring Bioscience
mouse monoclonal anti-brafv600e antibody, clone ve1
Mouse Monoclonal Anti Brafv600e Antibody, Clone Ve1, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/braf+v600e+antibody/10__1097_slash_pgp__0000000000000933-45-13-16
Average 90 stars, based on 1 article reviews
Mouse Monoclonal Anti Brafv600e Antibody, Clone Ve1, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/braf+v600e+antibody/10__1097_slash_pgp__0000000000000933-45-13-16
Average 90 stars, based on 1 article reviews
mouse monoclonal anti-brafv600e antibody, clone ve1 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Immunohistochemical staining:Article Title: Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status Article Snippet: International Journal of Gynecological Pathology 42:472–481, Lippincott Williams & Wilkins, Baltimore Copyright © 2023 by the International Society of Gynecological Pathologists Original Article Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status M. Herman Chui, M.D., Rajmohan Murali, M.B.B.S., M.D., F.R.C.P.A., Robert A. Soslow, M.D., Cathleen Matrai, M.D., Deyin Xing, M.D., P.hD., and Russell Vang, M.D.. Summary: Ovarian serous borderline tumors (SBTs) harboring the BRAFV600E mutation are associated with decreased risk of progression to low-grade serous carcinoma, and often prominently feature tumor cells with abundant eosinophilic cytoplasm.. Since eosinophilic cells (ECs) may be a marker of the underlying genetic driver, we proposed morphologic criteria and evaluated the interobserver reproducibility for assessing this histologic feature. Staining:Article Title: Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status Article Snippet: International Journal of Gynecological Pathology 42:472–481, Lippincott Williams & Wilkins, Baltimore Copyright © 2023 by the International Society of Gynecological Pathologists Original Article Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status M. Herman Chui, M.D., Rajmohan Murali, M.B.B.S., M.D., F.R.C.P.A., Robert A. Soslow, M.D., Cathleen Matrai, M.D., Deyin Xing, M.D., P.hD., and Russell Vang, M.D.. Summary: Ovarian serous borderline tumors (SBTs) harboring the BRAFV600E mutation are associated with decreased risk of progression to low-grade serous carcinoma, and often prominently feature tumor cells with abundant eosinophilic cytoplasm.. Since eosinophilic cells (ECs) may be a marker of the underlying genetic driver, we proposed morphologic criteria and evaluated the interobserver reproducibility for assessing this histologic feature. |
